1. Home
  2. SYBX vs GOVX Comparison

SYBX vs GOVX Comparison

Compare SYBX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synlogic Inc.

SYBX

Synlogic Inc.

N/A

Current Price

$1.14

Market Cap

15.2M

Sector

Health Care

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$0.18

Market Cap

12.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SYBX
GOVX
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.2M
12.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SYBX
GOVX
Price
$1.14
$0.18
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
77.3K
3.4M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,353,560.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.52
52 Week Low
$0.90
$0.12
52 Week High
$1.96
$2.75

Technical Indicators

Market Signals
Indicator
SYBX
GOVX
Relative Strength Index (RSI) 39.17 23.23
Support Level $1.14 $0.12
Resistance Level $1.28 $0.22
Average True Range (ATR) 0.07 0.04
MACD 0.02 -0.02
Stochastic Oscillator 59.26 19.83

Price Performance

Historical Comparison
SYBX
GOVX

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: